Advancements in Breast Cancer Treatments

This chapter discusses the Phase III study of camizestrant and its comparative effectiveness against fulvestrant, particularly in patients with ESR1 mutations. The conversation also explores ongoing clinical trials and treatment strategies for hormone receptor-positive, HER2-negative metastatic breast cancer, emphasizing personalized therapy based on patient characteristics.